AS/Spondyloarthritis
2 years ago
⬆️ correlation between BASDAI + ASQoL in 🙋♂️ vs 🙋♀️
What does this mean?
❓low disease activity in 🙋♀️ resulting in more marked ⬇️ in QoL❓
OR
❓Is there a need for gender stratified tools of disease activity❓
Abst#0406
#ACR22 @RheumNow @Sineadm15
2 years ago
Abstr 0373 created a scoring system to predict outcomes in SpA pts w/ uveitis
- Poor outcomes seen among smoking hx, females, +HLAB27, axial & peripheral involvement, high disease activity, inflammation, and b/l eye involvement
https://t.co/mGAn0Eel1O
@RheumNow #ACR22 https://t.co/qtJsavtG9z
2 years ago
ACR year in review: a summary of latest FDA approvals in spondyloarthritis by C. Langford
#ACRyearinreview #ACR22 @RheumNow https://t.co/u5TyRdQM7L
2 years ago
The new IL-17A/F inhibitor, bimekizumab, was comparable to current established therapies in active #AnkylosingSpondylitis. Check our NMA poster today. #ACR22 #SpA #medtwitter @TheBold_MD @cplch19 @UTSWRheum @ACRheum @RheumNow @DrCassySims https://t.co/vxa05r0GvS
There have been big advances in the treatment of axial spondyloarthritis (AxSpA) in the last decade.
Biologic drugs that target TNF and IL-17 have become mainstay treatments in AxSpA if the disease…
2 years ago
“Expert rheumatologist opinion remains the gold standard!” – Dr. J Scher on diagnosis of #axSpa
I would like to think this quote applies to everything, not just to axSpa (-my own opinion)
#ACRreview #ACR22 @rheumnow https://t.co/zpwQwXA8o2
When it comes to Spondyloarthritis we have numerous disease activity measures and much debate regarding best practices. When it comes to determining which to use in clinic, discrepancies occur. Do…
The pharmaceutical companies have will showcase their featured clinical trials and abstracts at ACR 2022. These are their best studies for you to review and evaluate as part of your to-do…
As we approach ACR22, there are many things to be excited about, especially with the reintroduction of in-person attendance. There are three areas that always draw my attention each conference and…
Poster Hall